Increased efficacy of gefitinib on cisplatin-resistant wild-type epidermal growth factor receptor non-small cell lung cancer cells.

ABSTRACT:

Background

Gefitinib is a first-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) that has become first-line treatment for patients with mutant EGFR non-small cell lung cancer (NSCLC). Despite its anti-tumor activity, the benefit of gefitinib in patients with wild-type EGFR NSCLC is debated. This work aimed to evaluate the effects of gefitinib on cisplatin-resistant wild-type EGFR NSCLC cells in in vitro and in vivo animal xenografts.

Methods

We established a cisplatin-resistant wild-type EGFR NSCLC cell line, H358^R, to evaluate the cells' sensitivity to gefitinib compared with that of parental cell line H358. We first tested the p-EGFR of gefitinib's target in H358^R and H358 cell line by western blot and imm

SUBMITTER: Li A 

PROVIDER: S-EPMC8798197 | biostudies-literature | 2020 Sep

REPOSITORIES: biostudies-literature